Septerna (NASDAQ:SEPN) Coverage Initiated at Jones Trading

Jones Trading started coverage on shares of Septerna (NASDAQ:SEPN) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set a “buy” rating and a $43.00 price target on the stock. Jones Trading’s target price suggests a potential upside of 45.91% from the stock’s previous close.

A number of other equities research analysts have also recently weighed in on the company. Raymond James Financial began coverage on shares of Septerna in a report on Friday. They set a “strong-buy” rating and a $38.00 price objective on the stock. Wall Street Zen upgraded shares of Septerna from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Wednesday, October 8th. HC Wainwright boosted their price target on Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Finally, Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $18.00 to $28.00 in a research report on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Septerna Trading Down 0.4%

Septerna stock opened at $29.47 on Tuesday. Septerna has a 1-year low of $4.17 and a 1-year high of $30.50. The company has a market capitalization of $1.32 billion, a P/E ratio of -19.52 and a beta of 3.76. The firm’s fifty day simple moving average is $23.87 and its 200-day simple moving average is $17.10.

Septerna (NASDAQ:SEPN) last released its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). The company had revenue of $21.50 million for the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. On average, equities research analysts predict that Septerna will post -7.11 earnings per share for the current year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the sale, the senior vice president directly owned 92,911 shares of the company’s stock, valued at approximately $1,677,972.66. This represents a 3.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. BVF Inc. IL boosted its holdings in Septerna by 79.3% in the 1st quarter. BVF Inc. IL now owns 4,396,124 shares of the company’s stock valued at $25,454,000 after purchasing an additional 1,944,100 shares during the period. Checkpoint Capital L.P. purchased a new position in Septerna in the 1st quarter worth approximately $4,776,000. ADAR1 Capital Management LLC purchased a new position in shares of Septerna in the first quarter worth $4,174,000. Perceptive Advisors LLC bought a new position in shares of Septerna during the second quarter valued at about $5,723,000. Finally, VR Adviser LLC purchased a new stake in Septerna in the 2nd quarter worth approximately $5,713,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.